Opportunity Costs

Clinical trials can bring new innovations to the market only when they are completed with the required number of patients. The problem is that only 6 percent of clinical trials are completed on time, and 80 percent of trials are delayed by at least one month. Additionally, 37 percent of all sites in any given trial fail to meet their enrollment targets, and more than 10 percent never enroll a single patient, meaning that such trials – and potentially helpful drugs – are stalled.

Acurian On: Opportunity Costs